New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Tourmaline Bio, Inc.
TRML
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

679M

Biotechnology

Next Earning date - 12 Nov 2024

679M

Biotechnology

Next Earning date - 12 Nov 2024

26.50USD
Shape0.27 ( 1.03%)
favorite-chart

Relative Strenght

74
favorite-chart

Volume Buzz

214%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

45%
OverviewChart

Quote Panel

Shape
Updated October 3, 2024
1W 6.00 % 1M 62.08 % 3M 111.49 % 1Y 121.76 %

Key Metrics

Shape

  • Market Cap

    679.50M

  • Shares Outstanding

    25.64M

  • Share in Float

    14.92M

  • Dividende

    15.118

  • Earning Date

    12 Nov 2024

  • Price Target

    26.5

  • Average Volume

    182093

  • Beta

    0

  • Range

    9.18-48.31

  • Industry

    Biotechnology

  • Website

    https://www.tourmalinebio.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

298.55x

P/S Ratio

2.02x

P/B Ratio

0.0

Debt/Equity

-1568.0%

Net Margin

$-1.9

EPS

How TRML compares to sector?

P/E Ratio

TRML

-19x

Relative Strength

Shape

TRML

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$10M

ShapeNaN%

2025-Revenue

$3.56

Shape-424%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

NA
vs NA

Q4.22

arrow
arrow

N/A

NA
vs NA

Q1.23

arrow
arrow

N/A

NA
vs NA

Q2.23

arrow
arrow

N/A

NA
vs NA

Q3.23

arrow
arrow

N/A

NA
vs NA

Q4.23

arrow
arrow

N/A

NA
vs NA

Q1.24

arrow
arrow

N/A

-0.55
vs NA

Q2.24

arrow
arrow

N/A

-0.68
vs NA

Q3.24

arrow
arrow

N/A

-0.82
vs NA

Q4.24

arrow
arrow

N/A

-0.86
vs NA

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

2.3M  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

0%

-0.00
vs -0.00

Q4.22

arrow
arrow

+0%

0
vs -0.00

Q1.23

arrow
arrow

-5%

-0.05
vs 0

Q2.23

arrow
arrow

+38%

0.38
vs -0.05

Q3.23

arrow
arrow

-5%

-0.05
vs 0.38

Q4.23

arrow
arrow

+1%

0.01
vs -0.05

Q1.24

arrow
arrow

-4%

-0.04
vs 0.01

Q2.24

arrow
arrow

-5%

-0.05
vs -0.04

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

TRML

globenewswire.com

7 hours ago

Tourmaline Bio to Present at Upcoming Investor Conferences
TRML

globenewswire.com

7 hours ago

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
TRML

globenewswire.com

7 hours ago

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
TRML

globenewswire.com

7 hours ago

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
TRML

globenewswire.com

8 hours ago

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
TRML

globenewswire.com

16 hours ago

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

New Feature Coming Soon, Stay Tuned!

ShapeShape